MentionFox
Home › Stakes › TriSalus Life Sciences, Inc.
5%+ stakes · Schedule 13D and 13G

TriSalus Life Sciences, Inc.: 5%+ holders

Who has reported owning 5% or more of TriSalus Life Sciences, Inc., from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more5
Filings10
Latest filing2026-07-07

TriSalus Life Sciences, Inc. has 10 Schedule 13D or 13G filings on record since 2025-08-01. 5 holders' latest filing reports 5% or more of common stock, $0.01 par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
Frankenius Equity AB14%6,989,748SCHEDULE 13D/A, 2025-08-042025-07-31
First Light Asset Management, LLC10.74%6,596,242SCHEDULE 13G/A, 2026-07-072026-06-30
Mats Wahlstrom6%2,987,881SCHEDULE 13D/A, 2025-08-012025-07-31
Utmost Group PLC5.71%3,503,385SCHEDULE 13G, 2026-05-122026-03-31
James J. Pallotta5.2%3,188,711SCHEDULE 13G/A, 2026-05-202026-05-15
Nantahala Capital Management, LLC4.09%2,040,245SCHEDULE 13G/A, 2025-11-142025-09-30

Purpose of Transaction (Item 4)

Mats Wahlstrom

Item 4 of the Statement is hereby amended and supplemented as follows: On June 23, 2025, the Issuer filed a Form S-4 announcing the Exchange Offer (the "Offer") of Common Stock in exchange for the shares of the Issuer's Preferred Stock, which equated to an exchange ratio of 3.3 shares of Common Stock for each share of Preferred Stock exchanged pursuant to the Offer. The Offer expired at one minute after 11:59 P.M. Eastern Daylight Time on July 23, 2025 and the conversions were completed on July 31, 2025. Leonard Capital, LLC. accepted the Exchange and was issued 165,000 shares of Common Stock in exchange for their 50,000 shares of Preferred Stock.Item 4 of the SCHEDULE 13D/A filed 2025-08-01

Frankenius Equity AB

Item 4 of the Statement is hereby amended and supplemented as follows: On June 23, 2025, the Issuer filed a Form S-4 announcing the Exchange Offer (the "Offer") of Common Stock in exchange for the shares of the Issuer's Preferred Stock, which equated to an exchange ratio of 3.3 shares of Common Stock for each share of Preferred Stock exchanged pursuant to the Offer. The Offer expired at one minute after 11:59 P.M. Eastern Daylight Time on July 23, 2025 and the conversions were completed on July 31, 2025. Frankenius Equity AB accepted the Exchange and was issued 759,000 shares of Common Stock in exchange for their 230,000 shares of Preferred Stock.Item 4 of the SCHEDULE 13D/A filed 2025-08-04

Timeline

FiledHolderPercentFiling
2025-08-01Mats Wahlstrom6%SCHEDULE 13D/A
2025-08-04Frankenius Equity AB14%SCHEDULE 13D/A
2025-08-14Nantahala Capital Management, LLC5.29%SCHEDULE 13G
2025-08-18Utmost Group PLC0.05%SCHEDULE 13G
2025-11-03Utmost Group PLC6.79%SCHEDULE 13G
2025-11-14Nantahala Capital Management, LLC4.09%SCHEDULE 13G/A
2026-05-12Utmost Group PLC5.71%SCHEDULE 13G
2026-05-15First Light Asset Management, LLC8.75%SCHEDULE 13G
2026-05-20James J. Pallotta5.2%SCHEDULE 13G/A
2026-07-07First Light Asset Management, LLC10.74%SCHEDULE 13G/A

Tools for this story

Each opens in a new tab, filled in for TriSalus Life Sciences, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/trisalus-life-sciences-1826667
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
TriSalus Life Sciences, Inc. 5%+ holders: 5 at 5% or more, largest Frankenius Equity AB 14%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/trisalus-life-sciences-1826667